Indeed, the tool compound U0126, which inhibits MEK in part due to its ability to chelate copper, is effective in reversing RASopathy phenotypes in iPSCs derived from patients with RAF1-associated NS and in BRAF- and MEK-associated CFC, as discussed above. Here, MAP2K7 is linked to RASopathy.